iPSC derived NK cell therapy / Ernexa Therapeutics - LARVOL DELTA

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire) - "The study...demonstrated a scalable platform for generating cell therapies comprising multiple immune cell types, such as NK cells and macrophages, derived from induced pluripotent stem (iPS) cells reprogrammed with mRNA. In vitro studies with lymphoid and myeloid cells showed synergistic killing of SKOV3 ovarian tumor cells. Furthermore, in an effort to improve how the iPSC-derived myeloid cells could target and engage solid tumors, the cells were transfected with mRNA encoding a humanized ROR1-CAR protein."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor